India’s drug regulatory authority Central Drugs Standard Control Organisation (CDSCO) has rejected a proposal from Dr Reddy’s Laboratories Ltd to conduct the next-level study in the country for evaluating Russia’s Sputnik-V COVID-19 vaccine and recommended to test it first in a smaller trial manner.
The expert panel of CDSCO has observed that enough data was not available on the safety and immunogenicity of the vaccine from the initial-stage trials abroad. The panel also notified that no inputs were available about Indian participants.
India’s move comes as a major setback for Russia’s plan to roll-out the vaccine before full trials and analyzing its effects. In the past few days, India has observed a flattening curve of cases with the country recording continuous dip in the number of active cases and deaths. Till now, the number of cases in India have reached around 68 lakh, of which over 58 lakh have recovered from the disease.
“The future of Indian agriculture depends on how well we can collaborate and innovate,” States…
Alok Kumar Agarwal, the former Managing Director of Alankit, emphasizes that sustainable finance is the…
The popular sports league, which garners significant viewership from India and abroad, has initiated its…
The total number of registered voters is more than the combined population of all European…
Who paid whom, how much and WHY? These are the general questions that everyone asked…
Alok Kumar Agarwal states, “The Indian FinTech sector is not just growing; it is revolutionizing…